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surgery occurred a mean of 4.2±2.5 years ago. Based on the HADS, 31% and 16% 
of patients had clinically meaningful anxiety and depression, respectively. 
Depression was significantly associated with poorer totaI IBDQ scores (p<0.0001) 
and higher BIQ scores (p<0.0001). Females are 2.15 times more likely to have 
anxiety than males (OR 2.15, 95% CI 1.19-3.88). Other factors associated with 
anxiety include loss of work productivity (OR 1.39, 95% CI 1.18-1.64) and poorer 
body image (OR 1.12, 95% CI 1.04-1.20). CONCLUSIONS: The findings from this 
multi-national study provide insight on important factors to inform patient-
physician communications both prior to and post-colectomy.  
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OBJECTIVES: Fatigue is the most common side-effect of treatment for chronic 
hepatitis C virus (CHC) infection with peginterferon-α and ribavirin (PR). 
Adequacy of the Fatigue Severity Scale (FSS) total scores for evaluating fatigue 
from the patients’ perspective in CHC trials was assessed using blinded data 
from two CHC clinical trials. METHODS: 386 treatment-naïve patients (PILLAR) 
and 462 treatment-experienced patients (ASPIRE) were randomized to receive 
simeprevir (TMC435), a potent, oral, once-daily, investigational HCV NS3/4A 
protease inhibitor in Phase III clinical development and PR or placebo/PR. 
Patients completed the FSS and EQ5D in their native language throughout the 72 
week trials. Reliability of the FSS was evaluated using Cronbach’s co-efficient a 
at Week 24 (internal consistency reliability) and intraclass correlation (ICC) 
between FSS at Weeks 12 and 24 in stable patients (<0.5 g/dL change in 
hemoglobin between Weeks 12/24). Concurrent validity was assessed as 
correlation with the EQ5D visual analog scale (VAS). Known-groups validity of 
FSS scores was assessed using mean comparison by levels on the EQ5D daily 
activity item and by clinician-rated fatigue AEs at Week 24. Distribution- and 
anchor-based methods identified values representing a meaningful change in 
individual and mean FSS scores. RESULTS: FSS scores were highly reliable 
(Cronbach’s α = 0.95, 0.96 and ICC: 0.74, 0.86 for PILLAR and ASPIRE, respectively). 
Concurrent validity (correlation of FSS and EQ5D VAS=-0.63, -0.66) and known 
groups validity (mean FSS scores by EQ5D daily activity levels or fatigue AEs 
severity (p < 0.05) were confirmed. Analyses suggest that a meaningful change in 
mean FSS scores ranges from 0.33-0.82, and that a 1 point change is a 
conservative indicator of an important within-subject change in FSS score. 
CONCLUSIONS: The Fatigue Severity Scale provides reliable and valid 
assessment and quantification of fatigue for clinical trials in patients with CHC 
infection.  
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Yen L1, Flood E2, Beusterien K3, Tucker J2, Stout B2, Ahmadi A2, Silberg DG1, Erder M1 
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OBJECTIVES: The purpose of this research was to develop an electronic daily sign 
and symptom diary, the Daily Ulcerative Colitis Scale (DUCS), including a patient 
reported outcomes (PRO) version for children 8-17 years and an observer 
reported outcomes (ObsRO) version for caregivers of children aged 5-10 years. 
METHODS: Open-ended one-on-one concept elicitation interviews were 
conducted with children aged 8-17 years with a documented history of mild to 
moderate ulcerative colitis confirmed by endoscopy, recruited from three clinical 
centers. The interviews focused on signs or symptoms associated with UC. In 
addition, five pediatric gastroenterologists and three nurses were interviewed 
about the pediatric UC signs/symptoms, and parent blogs on an active UC 
website were reviewed; the blogs included discussions on 26 children with UC. 
Interview transcripts were developed, and a thematic analysis was conducted in 
which each new concept identified was coded using MaxQDA. RESULTS: The 
concept elicitation interviews included 22 children in remission (six aged 8-12; 16 
aged 13-17) and 10 children with active disease (four aged 8-12; six aged 13-17). 
Information saturation (i.e., no new information reported in last patient 
interview) was achieved. A core set of seven signs/symptoms in pediatric UC 
emerged: abdominal pain, blood in stool, frequent stools, diarrhea, stool urgency, 
nocturnal stools, and tiredness. No substantial differences were observed across 
different ages, and descriptions were largely consistent across patients. Even 
when in remission, children reported occasional symptoms. The HCP interviews 
and blog data substantiated the interview findings; the HCPs confirmed that 
signs/symptoms of UC do not vary by age. CONCLUSIONS: Children with UC 
were able to report their signs/symptoms associated with UC, and these data 
informed the development of two measures with phrasing that should resonate 
with the pediatric and caregiver populations. These will be tested in cognitive 
debriefing interviews.  
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OBJECTIVES: To analysis of the pattern of the consumption of histamine H2-
receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) (ATC subgroup 
A02B) in Serbia in correlation with Scandinavian countries (Denmark, Norway, 
Sweden and Finland). METHODS: The data on consumption of medicines during 
the four-year period (2007-2010) have been provided from the databases of the 
national regulatory agencies. The results were expressed as the number of 
defined daily doses per 1000 inhabitants per day (DID). A qualitative analysis was 
carried out according to the drug utilization 90% (DU90%) approach. RESULTS: 
During the period 2007-2010, the overall consumption of A02B subgroup 
medicines in Serbia decreased by 7.8%, opposite to Scandinavian countries 
where the consumption continuously increased in all countries, up to 56% in 
Denmark. In 2010, H2RAs accounted for 71.78% (16.46DID) of medicines used 
within A02B subgroup in Serbia, while in Scandinavian countries the share of 
H2RAs was in the range of 1.08 DID in Sweden up to 5.75 DID in Norway. Despite 
the increase by 34.3%, consumption of PPIs in 2010 in Serbia (6.45 DID) was up to 
7.6 times lower than in the Scandinavian countries (49.1 DID in Denmark). The 
bulk of prescription (DU90%) in 2010 was made up of 3 (out of 7) medicines in 
Serbia, 2, 4 and 5 (out of 14) medicines in Sweden, Denmark and Finland 
respectively, and 5 (out of 10) medicines in Norway. Most frequently used 
medicine in Serbia was ranitidine (55.9%), in Sweden and Denmark omeprazole 
(80.3% and 30.3% respectively), in Norway esomeprazole (34.1%) and in Finland 
pantoprazole (28.5%). CONCLUSIONS: The overall utilization of medicines from 
A02B subgroup was notably lower in Serbia than in Scandinavian countries. 
Besides the quantity, the pattern of use showed significant differences 
suggesting that implementation of guidelines in Serbia is needed in order to 
achieve harmonization in prescribing practice.  
 
PGI27  
EVALUATION OF OUTPATIENT HEALTH CARE AND MEDICATION UTILIZATION 
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OBJECTIVES: Few studies have explored how utilization of outpatient services 
differ for HIV/HCV coinfected patients compared to HIV or HCV monoinfected 
patients. The objectives of this study were to compare annual outpatient clinic 
visit rates between coinfected and monoinfected patients and to compare 
utilization of HIV and HCV therapies between coinfected and monoinfected 
patients. METHODS: Data were retrieved from the 2005-2010 National Hospital 
Ambulatory Medical Care Surveys. Clinic visits with a primary or secondary ICD-
9-CM diagnosis code for HIV or HCV were included. Coinfection included visits 
with both HIV and HCV codes. Monoinfection included visits with only HIV or 
HCV codes. Patients <15 years of age at time of visit were excluded. Demographic 
characteristics and select comorbidities were compared by infection status using 
chi-square and ANOVA tests. Visit rates were computed using survey weights. 
RESULTS: Approximately 11,352,000 visits met study criteria for patients with 
HIV/HCV (8%), HIV (70%), or HCV (22%). The HCV cohort was older and had the 
highest proportion of females and whites as compared to HIV/HCV and HIV 
cohorts. The following comorbidities varied significantly across the three cohorts 
(HIV/HCV, HIV, HCV): current tobacco use (40%, 27%, 30%), depression (32%, 23%, 
24%), diabetes (9%, 10%, 17%), and chronic renal failure (<1%, 3%, 5%), (p<0.001 for 
all variables). HIV/HCV visit rates were lower than both HIV and HCV visits rates 
and varied little across all study years. In contrast, there was a decrease in 
annual HIV visit rates and an increase in annual HCV visit rates. HIV therapy 
utilization increased for both HIV/HCV and HIV cohorts; the increase was more 
pronounced in the HIV/HCV cohort. HCV therapy utilization remained low for 
both HIV/HCV and HCV cohorts for all years. CONCLUSIONS: Low utilization of 
HCV therapy for HIV/HCV patients and HCV patients warrants further 
investigation.  
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OBJECTIVES: A previous study indicated that after one year, the proportion of 
patients with a dose augmentation was higher with infliximab than with 
adalimumab. The objective of this study was to analyze, in a real world setting, 
trends in dose changes over a three-year period. METHODS: A retrospective 
cohort study was conducted using data from the Regie de l'assurance maladie du 
Quebec (RAMQ) for a randomly selected group of patients with a CD diagnosis, 
who had initiated (6month washout period) adalimumab or infliximab between 
February 2008 and March 2011. For adalimumab, dose increase was considered 
when the dose received exceeded 40mg every other week over at least an 8-week 
period. For infliximab, dose increase was considered either when the dose was 
increased or interval between doses was reduced for two periods of 8 weeks after 
the third injection. Statistical analyses were conducted using chi square test. 
RESULTS: The cohort included 1,517 patients (mean age: 33.9 years, 55.4% 
females). During the study period, 1,004 patients initiated infliximab (28 
previously used adalimumab) and 513 patients initiated adalimumab (195 
previously used infliximab). After 36 months, 28.2%(275/976) of patients with 
infliximab and 23.0%(73/318) of patients with adalimumab experienced a dose 
increase (p<0.05). For the non-naive patient subgroups, dose escalation occurred 
for 42.9%(12/28) with infliximab and for 27.2%(53/195) with adalimumab (p<0.05). 
Average annual cost of adalimumab was CDN$26,957 and CDN$18,577 for 
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patients with and without dose escalation, respectively, and CDN$29,504 and 
CDN$25,449 for infliximab in patients with and without dose escalation, 
respectively. CONCLUSIONS: Results of this RAMQ database analysis illustrate 
that, in a real-world setting and over a long period of time, CD patients treated 
with infliximab had a significantly higher proportion of dose escalation 
compared with patients treated with adalimumab. In both recommended and 
adjusted dosing, adalimumab demonstrated significant cost savings over 
infliximab.  
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OBJECTIVES: Assess the frequency and appropriateness of early repeated 
colonoscopy METHODS: Patients undergoing a colonoscopy in 2005 were identified 
using paid claims data from a nationwide privately insured population. Patients 
were screened to be between the ages of 50 and 64 years with at least one year 
continuous enrollment. Colonoscopies with evidence of positive results [e.g., paid 
claims for biopsy, fulguration, snare, etc.], or with evidence suggesting clinical 
indications three months prior to the screening were defined as non-screen tests. 
The cumulative probability of repeated screening colonoscopy was then 
documented and the related risk factors for appropriate and inappropriate repeat 
screening tests were assessed using survival analysis and Cox proportional hazard 
regression models. RESULTS: A total of 51,400 colonoscopies were identified from 
the paid claims in 2005 for patients age 50-64. The majority of these procedures 
were found to have either positive results [25,029 (48.7%)] or evidence of clinical 
indications for the procedure [17,842 (34.7%)]. Among 8,529 apparent screening 
colonoscopies with negative results, 8% had a repeated colonoscopy within six 
years, the majority of which were associated with evidence that the repeated test 
could be justified (78.7% with indications and 21.3% without indications). The initial 
regression analysis identified risk factors of repeated colonoscopy with indications 
including age over 55 (HR: 1.2; 95%CI: 1.0–1.5) and having at least one comorbidity 
(HR: 1.2; 95%CI: 1.0-1.5). The risk factors of repeated colonoscopy without 
indications include male (HR: 1.53; 95%CI: 1.07-2.20) and having at least one 
comorbidity (HR: 1.57; 95%CI: 1.04-2.31). CONCLUSIONS: The majority of all 
colonoscopies in 2005 were found not to be routine screening exams. The risk of a 
repeated screening colonoscopy within 6 years is low [8%]. Among these repeat 
procedures, the majority was done because of the existence of clinical indications.  
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OBJECTIVES: Tendon rupture is associated with fluoroquinolones and listed in 
boxed warnings. We reviewed and summarized reports of tendon rupture 
associated with fluoroquinolones as reported in the FDA’s Adverse Event 
Reporting System (FAERS) through September 26, 2012. METHODS: We queried 
the FAERS for reports of tendon rupture involving each fluoroquinolone. Signal 
detection consisted of empiric Bayes geometric mean (EBGM), with 95% 
confidence intervals from initial marketing date for each drug. For a signal to be 
considered significant, minimum criteria are: reports of 3 or more cases, the low 
end of the 95% confidence interval must be 2.0 or greater. RESULTS: There were 
2539 tendon rupture cases. Most cases were reported with levofloxacin (61.25%) 
followed by ciprofloxacin (23.87%) and moxifloxacin (9.05%). Signal detection 
results for fluoroquinolones were: ciprofloxacin (EBGM=20.0, 95%CI=18.2-21.6), 
enoxacin (EBGM=13.2, 95%CI=4.2-29.7), gatifloxacin (EBGM=5.0, 95%CI=3.5-7.0), 
levofloxacin (EBGM=55.2, 95%CI=52.3-58.0), moxifloxacin (EBGM=13.3, 
95%CI=11.7-15.1), norfloxacin (EBGM=9.6, 95%CI=6.5-13.5), ofloxacin (EBGM=8.2, 
95%CI=6.3-10.2), gemifloxacin (EBGM=1.9, 95%CI=0.7-4.5), lomefloxacin 
(EBGM=2.3, 95%CI=0.94-5), and trovafloxacin (EBGM=0.3, 95%CI=0.08-1.1). FAERS 
event date timelines suggest lower risk of tendon rupture for gemifloxacin (n=5), 
lomefloxacin (n=5), and trovafloxan (n=1), with initial reports in 2006, 2005, and 
2000, respectively. The mean age was 59.6± 5.1. The most common concurrent 
drugs were corticosteroids (levofloxacin=27.1%, enoxacin=20%, gatifloxacin 
=18.2%, moxifloxacin=14.7%, ciprofloxacin=10.4%, ofloxacin=5.3%, and 
norfloxacin=2.4%). Analysis by the reporting country revealed that most cases 
were reported from the US (70%) followed by Japan (8.2%), Great Britain (3.7%), 
France (.9%) and Canada (.42%). CONCLUSIONS: Tendon rupture was reported 
with most fluoroquinolones. Significant signals existed for all flouroquinolones 
except gemifloxacin, lomefloxacin, and trovafloxacin, which potentially have 
lower risks. However, FAERS data are dependent upon utilization and MedWatch 
reporting rates. As stated in the boxed warning, as stated in the boxed warning, 
concurrent corticosteroids increases risk of tendon rupture  
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OBJECTIVES: The purpose of this study was to investigate the risk of getting 
atrial fibrillation in a year after receiving the first medication and analyze cost-
effectiveness in avoiding the adverse event among alendronate, raloxifene, and 
hormone replacement therapy. METHODS: We used the 2000-2008 National 
Health Insurance Research Database (NHIRD) to identify 10,353 patients who had 
the first medication with drugs and classify them into three groups (7439 
patients defined as those who used alendronate and 2077 patients with 
raloxifene as well as 837 patients with hormone replacement therapy). Cox 
proportional hazard model was used to estimate the hazards of getting atrial 
fibrillation among three drugs. Also, this study used the cost-effectiveness 
analysis to estimate the incremental cost effective ratio in avoiding the adverse 
event as they were treated by different treatments. RESULTS: The Cox regression 
analyses demonstrated that alendronate group (HR=1.52, 95%CI: 0.55-4.19) and 
raloxifene group (HR=1.38, 95%CI: 0.46-4.21) had higher risk in getting atrial 
fibrillation than hormone replacement therapy group, but there were not 
statistically significant. As to the cost-effectiveness analysis in avoiding 1% 
chance of the adverse event, the average medication expenditure of hormone 
replacement therapy group would increase 2,916.7 USD (ICER=2,916.7, 95%CI: 
1063.3–5,102.9) and 2,266.7 USD (ICER=2,266.7, 95%CI: -411.5–5,068.1), comparing 
to alendronate group and raloxifene group respectively. CONCLUSIONS: People 
with osteoporosis that were treated by bisphosphonate or raloxifene are better in 
terms of overall economic cost than those who used hormone replacement 
therapy.  
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OBJECTIVES: Transforaminal Lumbar Interbody Fusion is used to treat 
mechanical back-pain and radicular pain associated with spondylolisthesis due 
to arthritis, herniated disc or spinal stenosis. This procedure is performed either 
in the traditional open technique (o-TLIF) or using minimally invasive (m-TLIF) 
techniques. The goal of this study was to conduct a meta-analysis to compare 
various outcomes when comparing treatments for lumbar spine conditions using 
the “standard” open fusion (o-TLIF) versus minimally invasive surgical fusion (m-
TLIF). METHODS: Prospective and retrospective cohort studies comparing o-TLIF 
to m-TLIF were identified by searching PubMed, EMBASE, the Cochrane libraries, 
and reference lists from selected studies. Of the 15 selected for full-text review, 4 
were excluded because they used the wrong surgical technique, did not include 
m-TLIF, or did not measure the desired outcomes. Effects sizes (relative risks and 
standardized mean differences) were calculated using both fixed- and random-
effects models. RESULTS: Eleven cohort studies (N=554 patients) were included 
in the review (N=259, o-TLIF; and N=294, m-TLIF). Average follow-up ranged from 
12 – 24 months. Random-effects models were used due to the high heterogeneity 
across studies for each outcome (53.1%-93.5%). Use of m-TLIF was associated 
with a 420 mL decrease in blood loss when compared to o-TLIF (standardized 
mean difference (SMD) = -1.57, 95% CI: -2.14 to -0.99, p<0.0001). Operating Room 
(OR) time was significantly longer with a 33 minute increase for those 
undergoing m-TLIF (SMD=0.90, 95% CI: 0.24 to 1.55, p=0.007). CONCLUSIONS: 
While most outcomes did not differ between the two procedures, m-TLIF was 
associated with significantly lower blood loss despite longer OR time. In the 
appropriate clinical population, m-TLIF may be the favorable TLIF procedure for 
treatment of back pain and radicular pain in patients with spondylolisthesis due 
to arthritis, herniated disc or spinal stenosis.  
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OBJECTIVES: Hip resurfacing (HR) was developed for younger, more active 
patients, as a surgical alternative to total hip arthroplasty (THA). The safety of 
metal-on-metal HR is controversial with concerns expressed over adverse events 
and early device failure. We conducted a systematic review comparing primary 
HR to conventional THA for patients with hip osteoarthritis (OA). Outcomes of 
interest were adverse event rates, early failure (revision/reoperation within 5 
years), and post-operative component alignment. METHODS: Studies were 
identified through electronic databases, grey literature and reference lists of 
included studies. Inclusion criteria were: English language studies published 
after 1996 reporting adverse events, complications, safety issues or revision rates 
with respect to adults with primary hip OA, who underwent either primary HR or 
THA. Outcomes of interest included: revision, reoperation, dislocation, 
infection/sepsis, femoral neck fractures, time to revision, rates of early failure, 
mortality, and post-operative component alignment. Results were reported per 
1000 person years for comparability and stratified by age, publication date and 
market status (in-use and discontinued). RESULTS: A total of 7421 abstracts were 
identified and screened. Of these 384 full text articles were reviewed, 236 of 
which were included in this analysis. For all devices, those in-use and 
discontinued, dislocations were more frequent in THA, while revisions and 
reoperations were more frequent in HR. An analysis of only devices currently in-
